CuraSen Therapeutics has commenced its Phase IIa proof-of-concept trial of CuraAX (CST-3056) with dosing of the first patient ...

An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR) agonist that mimics the effects of ...

Share on Pinterest A recent study used computational methods to identify novel compounds that activate receptors involved in pain modulation without sedation. Peter Dazeley/Getty Images Research on ...

Viatris Inc., a global healthcare company, and Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, announced that the US Food and Drug Administration (FDA) has approved ...